RDIF agrees on holding clinical trials of Russian coronavirus vaccine in India
MOSCOW. Sept 16 (Interfax) - The Russian Direct Investment Fund (RDIF) has come to an agreement on holding clinical trials of the coronavirus vaccine designed by the Gamaleya Institute in India, the RDIF press service said on Wednesday.
"The RDIF and Dr. Reddy's Laboratories Ltd. (Dr. Reddy's), a key global pharmaceutical company, have agreed to cooperate in the clinical trials and the supply of the Sputnik V vaccine to India," the press service said.
Once the agreement is approved by regulators, 100 million doses of the Sputnik V vaccine will be supplied to India, it said.
"Supply may begin at the end of 2020, after the results of the clinical trials become available and the vaccine is registered in India," the press service said.